DeepIntent today launched Helix AI, a platform the company describes as the first agentic AI system purpose-built for healthcare marketers, enabling tasks that previously required days or weeks of analytical work to be completed in minutes through natural language queries. The announcement, made June 15, 2026, in New York, marks a significant expansion of DeepIntent's technology stack and builds directly on the DeepIntent Helix marketing cloud the company released in March.

The launch compresses what has historically been one of the most friction-heavy workflows in pharmaceutical marketing - understanding prescriber and patient audiences, modeling market dynamics, building targetable segments, and activating those segments across channels - into a conversational interface that sits on top of existing healthcare data infrastructure. According to DeepIntent, the platform runs on data spanning nearly 4 million healthcare providers and 250 million patient lives.

What Helix AI does

At its core, Helix AI provides healthcare marketers with a natural language interface layered over DeepIntent's existing data and campaign infrastructure. The system is capable of handling six distinct categories of marketing work.

The first is audience intelligence. Marketers can query the full prescriber universe and consumer populations using plain language, surfacing audience size, geographic distribution, specialty composition, and prescribing behavior without writing SQL or navigating complex data dashboards.

The second category covers competitive and market analysis. The platform can analyze prescriber overlap between products, examine longitudinal prescribing trends, and identify growth opportunities - the kind of analysis that typically requires a specialist analyst and several days of data preparation.

Third, the system integrates healthcare provider and direct-to-consumer insights within a single conversation. Rather than running separate queries against separate datasets and then reconciling the outputs manually, marketers can explore both audiences simultaneously and ask follow-up questions that draw on both pools of data at once.

Fourth, Helix AI handles audience creation and activation. Marketers can build HealthFirst HCP and DTC audiencesusing natural language, then push those audiences directly to DeepIntent's DSP or to social platforms without leaving the interface. According to DeepIntent, this collapses a workflow that previously involved multiple teams and tools into a single conversational session.

Fifth, the system provides media performance optimization. This includes cross-channel forecasts, reach estimates, and AI-generated recommendations - not just descriptive reporting but forward-looking guidance on where a campaign budget will generate the most impact.

Sixth and finally, Helix AI supports in-flight campaign evaluation. Marketers can query live campaign data in natural language and retrieve media and healthcare-specific key performance indicators, including Audience Quality (AQ), verified HCP reach, doctor visitation rates, and new patient start counts. These are metrics that matter specifically to pharmaceutical clients and that generic advertising measurement tools rarely surface in isolation.

The infrastructure underneath

Helix AI is not a standalone product. It sits on top of DeepIntent Helix, the healthcare marketing cloud DeepIntent announced on March 19, 2026 at the company's AdLab annual forum for senior healthcare marketing leaders. That platform was itself a significant shift in how DeepIntent operates - moving from a self-contained demand-side platform into an infrastructure provider whose data stack could be accessed by third-party partners.

According to DeepIntent, the Helix foundation reflects a decade of investment in health data infrastructure. The datasets it draws on cover clinical, identity, and media data in a HIPAA-compliant environment, meaning the conversational layer of Helix AI can access sensitive health information without routing it through unsecured general-purpose AI models. That distinction matters considerably in healthcare marketing, where the regulatory stakes of data mishandling are high and where advertisers cannot rely on the kind of broad, probabilistic data pipelines common in consumer advertising.

The company emphasizes that the conversational interface sits on top of this trusted infrastructure - not on a generic large language model bolted onto loosely organized data. The architecture is designed so that the compliance posture of the underlying data is not compromised when marketers query it in plain language.

Chris Paquette, Founder and CEO of DeepIntent, framed the launch in terms of information access. "From my own experience working in healthcare, the speed at which information reaches patients and providers has a significant impact on improving patient outcomes and quality of life. Agentic AI presents us with the technology to finally democratize access to critical insights buried deep within varying types of health and media data," Paquette said. "Helix AI shrinks both the time-to-insight and time-to-action from weeks to minutes, representing a major advance in how healthcare marketers can use AI and data to optimize the commercial success of their therapeutic products."

Beta results and agency adoption

DeepIntent has disclosed one concrete performance figure from the Helix AI beta period: agencies that used the platform reduced their planning cycle time by 50%. The beta involved agencies as the primary user group, with those organizations using Helix AI as a planning resource rather than primarily as a campaign execution tool. According to DeepIntent, full client access began today.

Agencies will also be able to extend the platform with proprietary assets. According to DeepIntent, agencies can integrate first-party analytics, first-party data, and owned media into the Helix AI environment, allowing the natural language interface to draw on agency-specific resources alongside DeepIntent's core datasets. That customization layer is intended to give agencies a differentiated product they can present to clients under their own brand.

Two agencies that participated in the beta have publicly commented on the results. Sharona Sankar-King, Chief Data and Product Officer of Havas Media Network North America, described the change in practical terms: "DeepIntent has long been a trusted partner in helping us unlock the full potential of health data. Helix AI represents a meaningful leap forward in how quickly we can understand market dynamics, identify opportunities, and bring stronger recommendations to clients. The speed at which we can now surface actionable insights has fundamentally changed how we approach strategy and new business."

Liz Mansell, SVP of Media Strategy at Fingerpaint Marketing, addressed the depth of analysis the platform enables: "Helix AI provides a strategic edge by putting advanced, purpose-built data capabilities directly into the hands of our strategists. Analysis that once took days, and often wasn't feasible at this depth, now takes minutes. We're operating at a level of intelligence that sets a new standard for what nimble agencies committed to pioneering AI innovation can deliver."

A pattern of expansion in 2026

The Helix AI launch arrives at the end of a period of concentrated product activity for DeepIntent. Since the start of the year, the company has moved to expand its footprint across supply categories and data types simultaneously.

In May 2026, DeepIntent opened access to three point-of-care partners, connecting its platform to electronic health record environments for the first time. That announcement included integrations with OptimizeRx, epocrates, and Lane4.io, collectively adding EHR inventory to a DSP that had previously focused on open-web programmatic, CTV, and audio. Point-of-care media spend surpassed $1 billion in 2024, according to industry figures cited at the time, and the channel had historically been difficult to activate programmatically.

Earlier in June, DeepIntent announced verified live CTV inventory for pharmaceutical advertisers. That product, reported by PPC Land on June 13, gave pharma brands access to live sports and events programming - World Cup, NFL, and NBA inventory - with pre-bid confirmation that placements were airing in verified live sports contexts before any bid was submitted. According to DeepIntent, 96 of the 100 most-watched telecasts in the United States in 2025 featured live sports, a concentration of viewership that pharmaceutical advertisers had previously been unable to access with confidence because verification infrastructure was absent.

The epocrates integration, announced May 26, 2026, provided programmatic access to over one million active clinicians within a logged-in, authenticated environment - the kind of deterministic identity that HIPAA-governed healthcare advertising requires.

Taken together, these launches suggest a deliberate strategy of expanding what a healthcare DSP can do, moving from a point solution for programmatic display and video into a platform that combines data infrastructure, audience intelligence, channel access, and - now - an AI-powered planning and analysis layer.

The agentic AI context

DeepIntent is not the first advertising technology company to introduce an agentic AI layer over its data and campaign infrastructure, but it may be the first to do so specifically for healthcare marketing with data built to pharmaceutical compliance standards.

The broader ad tech industry has been moving toward agentic systems since late 2025. Yahoo DSP launched agentic AI capabilities in January 2026, enabling advertisers to automate campaign setup, troubleshooting, and optimization through natural language. PubMatic followed with its AgenticOS, reported by PPC Land in January 2026, positioning agentic AI as a potential replacement for some traditional DSP functions. LiveRamp introduced agentic AI tools for marketing automation in October 2025, adding over 25 partner integrations alongside its AI capabilities.

What differentiates Helix AI from these general-purpose implementations is the underlying data. Healthcare marketing data is not interchangeable with consumer advertising data. Prescriber behavior, patient population data, and clinical outcomes are governed by federal law in the United States. Generic agentic systems built on consumer data infrastructure cannot legally or practically handle that information. DeepIntent's argument is that the HIPAA-compliant foundation of DeepIntent Helix makes the conversational layer of Helix AI viable in a regulated context where competitors without similar infrastructure cannot operate.

The distinction has become more relevant as agentic AI has begun to challenge traditional DSP business models, a concern that industry analyst Ari Paparo raised in July 2025. His analysis suggested that autonomous AI systems could eventually automate campaign setup, targeting, and optimization functions currently handled by demand-side platforms. DeepIntent's approach - embedding agentic capabilities within its own DSP rather than allowing them to operate independently - is one response to that structural challenge.

Why healthcare is different

For context, healthcare advertising operates under constraints that most other advertising categories do not face. The Health Insurance Portability and Accountability Act governs how patient-level information can be used, restricting the kinds of data pipelines that consumer platforms rely on. Pharmaceutical companies advertising prescription drugs must additionally comply with Food and Drug Administration guidance on fair balance, meaning a single ad placement in the wrong context can create regulatory exposure, not just reputational risk.

The practical consequence is that pharmaceutical marketers require more verification, more specificity, and more measurement precision than consumer advertisers. Reaching a verified cardiologist is worth considerably more than reaching someone probabilistically identified as a healthcare professional. Knowing that a campaign correlated with new patient starts - a metric DeepIntent calls script lift - is more valuable than knowing it generated impressions.

Helix AI's design reflects those requirements. The ability to query prescribing behavior, specialty composition, and patient population characteristics in natural language reduces the time between a strategic question and a data-backed answer. The ability to build and activate an audience in the same conversation, without a separate workflow or handoff to a different team, removes a step that routinely added days to campaign timelines.

US healthcare digital advertising spending is projected to surpass $20 billion in 2026, according to figures cited in earlier PPC Land coverage of pharmaceutical advertising developments. The scale of that market makes even incremental efficiency gains significant. A 50% reduction in planning cycle time, if the beta figure holds across a broader deployment, would materially change how pharmaceutical brands and their agencies staff and schedule campaign work.

Timeline

Summary

Who: DeepIntent, a New York-based healthcare demand-side platform, along with early adopters Havas Media Network North America and Fingerpaint Marketing.

What: The launch of Helix AI, described as the first agentic AI platform purpose-built for healthcare marketers, enabling natural language queries across prescriber data, patient populations, competitive market trends, audience building, and campaign performance measurement. Beta agencies reported a 50% reduction in planning cycle time.

When: Announced and made available to clients on June 15, 2026. The platform is built on the DeepIntent Helix marketing cloud, which launched on March 19, 2026.

Where: DeepIntent is headquartered in New York. The platform is available to DeepIntent's existing client base globally, with audience activation running through DeepIntent's DSP and social platforms.

Why: Life sciences companies face commercial pressure to launch products faster and demonstrate measurable outcomes. Healthcare marketing data - covering prescribers, patients, and clinical behavior - is distributed across datasets that have historically required specialist analysts and days or weeks of work to navigate. Helix AI attempts to compress that timeline into minutes using conversational AI, on top of HIPAA-compliant infrastructure that general-purpose AI tools cannot access.